<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794351</url>
  </required_header>
  <id_info>
    <org_study_id>22P5</org_study_id>
    <nct_id>NCT01794351</nct_id>
  </id_info>
  <brief_title>Cognitive Effects of 500mg Trans-resveratrol</brief_title>
  <official_title>Effects of Trans-resveratrol on Cognitive Performance in Healthy, Young Humans: a Double-blind, Placebo-controlled, Crossover Investigation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northumbria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northumbria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigated the potentially cognitive enhancing effects of 500mg
      trans-resveratrol in healthy, young humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with altered cognitive function at 40mins post-dose</measure>
    <time_frame>40mins Post-dose</time_frame>
    <description>This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from the baseline to 40min post-dose scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with altered cognitive function at 2.5hrs post-dose</measure>
    <time_frame>2.5hrs post-dose</time_frame>
    <description>This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 2.5hr post-dose scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with altered cognitive function at 4hrs post-dose</measure>
    <time_frame>4hrs post-dose</time_frame>
    <description>This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 4hr post-dose scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with altered cognitive function at 6hrs post-dose</measure>
    <time_frame>6hrs post-dose</time_frame>
    <description>This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 6hr post-dose scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with altered mood at 40mins post-dose.</measure>
    <time_frame>40mins post-dose</time_frame>
    <description>This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 40mins post-dose scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with altered mood at 2.5hrs post-dose</measure>
    <time_frame>2.5hrs post-dose</time_frame>
    <description>This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 2.5hrs post-dose scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with altered mood at 4hrs post-dose</measure>
    <time_frame>4hrs pos-dose</time_frame>
    <description>This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 4hrs post-dose scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with altered mood at 6hrs post-dose</measure>
    <time_frame>6hrs post-dose</time_frame>
    <description>This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 6hrs post-dose scores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cognitive Performance</condition>
  <condition>Mood</condition>
  <arm_group>
    <arm_group_label>Placebo then resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm (decided according to Latin square) first received placebo and then resveratrol, on seperate days, with a 7-14 day wash-out period between visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resveratrol then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm (decided according to Latin square) first received resveratrol and then placebo, on seperate days, with a 7-14 day wash-out period between visits</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Trans-resveratrol</intervention_name>
    <description>In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.</description>
    <arm_group_label>Placebo then resveratrol</arm_group_label>
    <arm_group_label>Resveratrol then placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.</description>
    <arm_group_label>Placebo then resveratrol</arm_group_label>
    <arm_group_label>Resveratrol then placebo</arm_group_label>
    <other_name>Pharmaceutical grade silica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-35yrs, healthy.

        Exclusion Criteria:

          -  Drug/alcohol abuse, taking prescription medication (apart from contraception) or
             herbal supplements, having food intolerances or allergies, having suffered a
             head-injury or neurological/neuro-developmental disorder, uncorrected sight problems,
             pregnant or seeking to become so, excessive caffeine use (e.g. more than 6 cups of
             coffee per day).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brain performance and nutrition research centre, Northumbria university</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne and Wear</state>
        <zip>NE1 8ST</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2013</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northumbria University</investigator_affiliation>
    <investigator_full_name>David Kennedy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

